Wei-Ping Lu

机构：Nanjing Medical University · ORCID：0000-0002-6322-6897

发表论文 25 篇 · 总被引 687 次 · h-index 8

代表论文

• Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers (2015 · Cancer Cell · 被引 313)
• Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells (2015 · Journal of Medicinal Chemistry · 被引 85)
• Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 (2015 · Molecular Cancer Therapeutics · 被引 81)
• Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages (2021 · Molecular Cancer Therapeutics · 被引 73)
• Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT) (2022 · Bioorganic & Medicinal Chemistry Letters · 被引 44)
• Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region (2010 · Bioorganic & Medicinal Chemistry Letters · 被引 35)